Please login to the form below

Not currently logged in
Email:
Password:

Alector kicks off next wave of biotech IPOs

US biotech raising money again

alector

The US government shutdown of 35 days had deterred new IPOs in biotech, but market launches have now resumed with immune-neurology specialists Alector.

The San Francisco-based company floated on the Nasdaq yesterday, raising $176m and hitting its forecast market capitalisation of $1.3 bn.

Alector is pioneering immuno-neurology, a novel therapeutic that will treat a range of degenerative brain disorders by restoring healthy immune function to the brain.

Rosenthal

Arnon Rosenthal

Arnon Rosenthal, an ex-Genentech researcher, is the company’s co-founder and chief executive, and says its discovery platform combination of insights from human genetics and immunology can overcome disappointments seen in neurology, most especially in Alzheimer’s disease.

Its initial focus is on frontotemporal dementia (AL001 entering phase 1 trials in September) and Alzheimer’s disease, AL002 also entering phase 1 in December.

Hot on Alector’s heels is Stealth BioTherapeutics, which is aiming to raise $81 million, capital it will put towards its late-phase candidates which target mitochondria dysfunction.

In December the Boston-based company gained a valuable FDA fast track designation for its lead candidate, elamipretide, a treatment for dry age-related macular degeneration (AMD), for which there are currently no licensed treatments.

A third IPO expected this week is from Gossamer, a San Diego-based biotech specialising in in-licensing molecules in immunology, inflammation and oncology.

The company is led by Faheem Hasnain and Sheila Gujrathi, two former execs from Receptos - the company bought out by Celgene four years ago for $7.2bn.

Its plans had also been disrupted by the government shutdown, but is now on track again, and hopes to raise $276m from its stock flotation today.

Article by
Andrew McConaghie

8th February 2019

From: Marketing

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Nucleus Global

Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 800 experts delivering world-class...

Latest intelligence

How nature can help you manage the pressures of agency life
Paul Hutchings, founder of fox&cat, outlines how nature can help you can boost staff wellbeing in your agency this Mental Health Awareness Week...
How can we strike the right balance between familiarity and innovation when it comes to data presentation?
Following our webinar in March, Getting MedComms right: navigating the age of the amateur expert, we’re taking the time to respond to questions we were unable to answer during the...
Deep 6 AI: the smart software breathing new life into clinical trials
Fishawack Health interviews Wout Brusselaers, the Deep 6 AI CEO using artificial intelligence to solve one of the greatest barriers stagnating healthcare innovation—clinical trial recruitment and retention....